Wednesday, October 1st, 2025
Market UpdatesSingapore SGX stocks

Wilmar International Downgraded to HOLD Amid Indonesian Regulatory Scrutiny – 2025 Outlook, Dividend Cut & Growth Prospects

Posted on September 30, 2025 at 9:53 am (GMT+8)

87
Views
Share on Facebook
Share on Twitter

Broker: Maybank Research Pte Ltd
Date of Report: September 29, 2025
Excerpt from Maybank Research Pte Ltd report.

Report Summary

  • Wilmar International is downgraded to HOLD by Maybank, with a target price cut by 18% to SGD3.0, primarily due to ongoing regulatory scrutiny and reputation risks in Indonesia and penalties related to cooking oil.
  • Despite these challenges, Wilmar is expected to post 7% revenue and 13% NPAT CAGR for 2024–27, supported by resilient demand in China and stable crush margins, while valuations and dividend yield provide downside support.

Above is an excerpt from a report by Maybank Research Pte Ltd. Clients of Maybank Research Pte Ltd can be the first to access the full report from the Maybank website : www.maybank-keresearch.com

Related Posts

Bursa KLSE stocksMarket Updates

Eco World Development Secures MYR694M Land Deal with Microsoft: Analyst Maintains BUY Rating
minichart
February 18, 2025

Comprehensive Analysis of Eco World Development and Notable Transactions Comprehensive Analysis of Eco World Development and Notable Transactions Broker Name: Maybank Investment Bank Berhad Date of Report: February 18, 2025 Eco World Development (ECW...

Hong Kong stocksMarket UpdatesSingapore SGX stocks

Singapore Market Update: Hongkong Land’s Strategic Moves, Metro Holdings’ Losses & Institutional Fund Flows – May 2025 Insights
minichart
May 23, 2025

Broker: Lim & Tan Securities Date of Report: 23 May 2025 Singapore Market Insights: Key Stock Picks, Fund Flows, and Sector Performance for May 2025 Market Overview: STI Performance and Global Market Snapshots The...

Hong Kong stocksMarket Updates

Sino Biopharmaceutical Ltd Positioned for Strong Gains with Technical Buy Momentum
minichart
September 17, 2024

Date: September 17, 2024Broker: CGS-CIMB Securities Company Overview Sino Biopharmaceutical Ltd (Stock Code: 1177) is a major pharmaceutical company based in Hong Kong. It focuses on the research, development, production, and distribution of biopharmaceutical...